



## Voyager Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

02/29/16

CAMBRIDGE, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that Steven Paul, M.D., president and chief executive officer, will present a company overview at the Cowen and Company 36<sup>th</sup> Annual Health Care Conference on Wednesday, March 9, 2016 at 8:00 a.m. ET in Boston, MA.

A live audio webcast of the presentation can be accessed through the Investors & Media section of Voyager's website at [www.voyagertherapeutics.com](http://www.voyagertherapeutics.com). The webcast will be archived for 30 days after the live event concludes.

### About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company's pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Genzyme Corporation, a Sanofi company, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit [www.voyagertherapeutics.com](http://www.voyagertherapeutics.com). Follow Voyager on [LinkedIn](#).

Contact: ☐

Investor Relations:

Sarah McCabe

Stern Investor Relations, Inc.

212-362-1200 ☐

[sarah@sternir.com](mailto:sarah@sternir.com)

Media: ☐

Katie Engleman

Pure Communications, Inc.

910-509-3977 ☐

[Katie@purecommunicationsinc.com](mailto:Katie@purecommunicationsinc.com)



Voyager Therapeutics